BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

525 related articles for article (PubMed ID: 33325394)

  • 1. Clinical Experience with Eculizumab in Treatment-Refractory Acetylcholine Receptor Antibody-Positive Generalized Myasthenia Gravis.
    Katyal N; Narula N; Govindarajan R
    J Neuromuscul Dis; 2021; 8(2):287-294. PubMed ID: 33325394
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Retrospective Analysis of Eculizumab in Patients with Acetylcholine Receptor Antibody-Negative Myasthenia Gravis: A Case Series.
    Datta S; Singh S; Govindarajan R
    J Neuromuscul Dis; 2020; 7(3):269-277. PubMed ID: 32444555
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study.
    Howard JF; Utsugisawa K; Benatar M; Murai H; Barohn RJ; Illa I; Jacob S; Vissing J; Burns TM; Kissel JT; Muppidi S; Nowak RJ; O'Brien F; Wang JJ; Mantegazza R;
    Lancet Neurol; 2017 Dec; 16(12):976-986. PubMed ID: 29066163
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Eculizumab in Adolescent Patients With Refractory Generalized Myasthenia Gravis: A Phase 3, Open-Label, Multicenter Study.
    Brandsema JF; Ginsberg M; Hoshino H; Mimaki M; Nagata S; Rao VK; Ruzhansky K; Suresh N; Tiongson E; Yamanouchi H; Frick G; Hicks E; Liao S; Howard JF;
    Pediatr Neurol; 2024 Jul; 156():198-207. PubMed ID: 38810600
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 'Minimal symptom expression' in patients with acetylcholine receptor antibody-positive refractory generalized myasthenia gravis treated with eculizumab.
    Vissing J; Jacob S; Fujita KP; O'Brien F; Howard JF;
    J Neurol; 2020 Jul; 267(7):1991-2001. PubMed ID: 32189108
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Successful Transition from Plasma Exchange to Eculizumab in Acetylcholine Receptor Antibody- and Muscle-Specific Kinase (MuSK) Antibody-Negative Myasthenia Gravis: A Case Report.
    Greenwood GT; Lynch Z
    Am J Case Rep; 2020 May; 21():e921431. PubMed ID: 32417849
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The use of eculizumab in ventilator-dependent myasthenia gravis patients.
    Usman U; Chrisman C; Houston D; Haws CC; Wang A; Muley S
    Muscle Nerve; 2021 Aug; 64(2):212-215. PubMed ID: 34008175
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term efficacy of eculizumab in refractory generalized myasthenia gravis: responder analyses.
    Howard JF; Karam C; Yountz M; O'Brien FL; Mozaffar T;
    Ann Clin Transl Neurol; 2021 Jul; 8(7):1398-1407. PubMed ID: 34043280
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Eculizumab: A Review in Generalized Myasthenia Gravis.
    Dhillon S
    Drugs; 2018 Mar; 78(3):367-376. PubMed ID: 29435915
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and outcomes of eculizumab for acetylcholine receptor-positive generalized myasthenia gravis in clinical practice.
    Suh J; Clarke V; Amato AA; Guidon AC
    Muscle Nerve; 2022 Sep; 66(3):348-353. PubMed ID: 35684980
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Eculizumab improves fatigue in refractory generalized myasthenia gravis.
    Andersen H; Mantegazza R; Wang JJ; O'Brien F; Patra K; Howard JF;
    Qual Life Res; 2019 Aug; 28(8):2247-2254. PubMed ID: 30905021
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efgartigimod and Ravulizumab for Treating Acetylcholine Receptor Auto-antibody-Positive (AChR-Ab+) Generalized Myasthenia Gravis: Indirect Treatment Comparison.
    van Steen C; Celico L; Spaepen E; Hagenacker T; Meuth SG; Ruck T; Smith AG; Bodicoat DH; de Francesco M; Iannazzo S
    Adv Ther; 2024 Jun; 41(6):2486-2499. PubMed ID: 38642198
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Real-world experience with eculizumab and switching to ravulizumab for generalized myasthenia gravis.
    Tokuyasu D; Suzuki S; Uzawa A; Nagane Y; Masuda M; Konno S; Kubota T; Samukawa M; Sugimoto T; Ishizuchi K; Oyama M; Yasuda M; Akamine H; Onishi Y; Suzuki Y; Kawaguchi N; Minami N; Kimura T; Takahashi MP; Murai H; Utsugisawa K
    Ann Clin Transl Neurol; 2024 May; 11(5):1338-1346. PubMed ID: 38572524
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and effectiveness of eculizumab in Japanese patients with generalized myasthenia gravis: interim analysis of post-marketing surveillance.
    Murai H; Suzuki S; Hasebe M; Fukamizu Y; Rodrigues E; Utsugisawa K
    Ther Adv Neurol Disord; 2021; 14():17562864211001995. PubMed ID: 33796147
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomized, double-blind, placebo-controlled phase II study of eculizumab in patients with refractory generalized myasthenia gravis.
    Howard JF; Barohn RJ; Cutter GR; Freimer M; Juel VC; Mozaffar T; Mellion ML; Benatar MG; Farrugia ME; Wang JJ; Malhotra SS; Kissel JT;
    Muscle Nerve; 2013 Jul; 48(1):76-84. PubMed ID: 23512355
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term safety and efficacy of eculizumab in generalized myasthenia gravis.
    Muppidi S; Utsugisawa K; Benatar M; Murai H; Barohn RJ; Illa I; Jacob S; Vissing J; Burns TM; Kissel JT; Nowak RJ; Andersen H; Casasnovas C; de Bleecker JL; Vu TH; Mantegazza R; O'Brien FL; Wang JJ; Fujita KP; Howard JF;
    Muscle Nerve; 2019 Jul; 60(1):14-24. PubMed ID: 30767274
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Responsiveness to Tocilizumab in Anti-Acetylcholine Receptor-Positive Generalized Myasthenia Gravis.
    Jia D; Zhang F; Li H; Shen Y; Jin Z; Shi FD; Zhang C
    Aging Dis; 2024 Apr; 15(2):824-830. PubMed ID: 37450932
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Post-intervention Status in Patients With Refractory Myasthenia Gravis Treated With Eculizumab During REGAIN and Its Open-Label Extension.
    Mantegazza R; Wolfe GI; Muppidi S; Wiendl H; Fujita KP; O'Brien FL; Booth HDE; Howard JF;
    Neurology; 2021 Jan; 96(4):e610-e618. PubMed ID: 33229455
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Eculizumab in refractory generalized myasthenia gravis previously treated with rituximab: subgroup analysis of REGAIN and its extension study.
    Siddiqi ZA; Nowak RJ; Mozaffar T; O'Brien F; Yountz M; Patti F;
    Muscle Nerve; 2021 Dec; 64(6):662-669. PubMed ID: 34590717
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of ravulizumab in patients with generalized myasthenia gravis by time from diagnosis: A post hoc subgroup analysis of the CHAMPION MG study.
    Howard JF; Vu T; Mantegazza R; Kushlaf H; Suzuki S; Wiendl H; Beasley KN; Liao S; Meisel A;
    Muscle Nerve; 2024 May; 69(5):556-565. PubMed ID: 38380691
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.